BioCardia, Inc. SEC Filings

BioCardia, Inc. filed a Current Report stating that, as of the report date, it believes it has regained compliance with Nasdaq's minimum $2.5 million stockholders' equity requirement for continued listing. The company notes that stockholders' equity exceeds $2.5 million as of the date of the report but warns Nasdaq will continue to monitor ongoing compliance and could initiate delisting proceedings if compliance is not maintained at the time of its next periodic report. The filing also includes standard forward-looking statement disclaimers referencing the company's annual and quarterly reports.

Simon H. Stertzer, a director of BioCardia, Inc. (BCDA), reported purchases and related holdings on Form 4. He participated in a public offering that closed on 09/19/2025, purchasing 398,400 shares of common stock at $1.25 per share and receiving 398,400 warrants exercisable into one share each at $1.25. The warrants are dated 09/19/2025 and expire 09/20/2027. After the reported transactions the filing shows 591,054 shares beneficially owned indirectly by entities tied to the reporting person, and several pre-existing holdings across trusts and LLCs are disclosed. The Form 4 is signed by power of attorney on 09/23/2025.

BioCardia insider purchase reported on Form 4: Director Andrew Scott (reporting as Andy Blank Revocable Living Trust) purchased 288,000 shares of common stock and received 288,000 warrants on 09/19/2025 at a price of $1.25 per share/warrant bundle. After the transaction the reporting person beneficially owned 634,023 shares (direct/indirect holdings) and held warrants exercisable into 288,000 shares expiring 09/20/2027. The filing notes the shares are held in a revocable trust for which the reporting person is trustee. The Form 4 was signed by power of attorney on 09/23/2025.

Insider purchase reported for BioCardia, Inc. (BCDA). Peter Altman, the company's President, CEO and a director, purchased 48,000 shares of common stock at $1.25 per share on 09/19/2025 through a public offering that closed that day, and received 48,000 warrants exercisable at $1.25 expiring 09/20/2027. After the transaction Mr. Altman beneficially owned 216,762 shares of common stock and 143,612 derivative securities (warrants/options) on a direct basis. The Form 4 was signed under power of attorney on 09/23/2025.

BioCardia, Inc. filed an 8-K to report that it has had a positive preliminary clinical consultation with Japan’s Pharmaceutical and Medical Devices Agency (PMDA) regarding the CardiAMP Heart Failure Trial results previously provided to the agency.

The meeting was held to prepare for a formal clinical consultation on whether the trial data will be acceptable for submission of an application for product approval in Japan. BioCardia also furnished the related press release as an exhibit to this report.

Lincoln Alternative Strategies LLC reported beneficial ownership of 800,000 shares of BioCardia, Inc. common stock, representing 7.54% of the outstanding shares based on 10,608,734 shares outstanding as of September 19, 2025. The filing lists sole voting and dispositive power over all 800,000 shares and indicates the holder is organized in Delaware. The filing includes a certification that the securities were not acquired to change or influence control of the issuer. Contact and address details for the issuer and filer are provided in the statement.

BioCardia, Inc. completed a registered offering on September 19, 2025, selling 4,800,000 shares of common stock together with warrants to purchase up to 4,800,000 shares at a combined price of $1.25 per share and warrant, generating approximately $6.0 million in gross proceeds. Certain directors and executive officers purchased 734,400 shares and warrants for roughly $0.9 million. The company expects net proceeds of about $5.1 million after placement agent fees and offering expenses. Each warrant is exercisable at $1.25, immediately exercisable, and expires September 20, 2027, subject to customary anti-dilution adjustments and beneficial ownership exercise limits (default 4.99% or elective 9.99% with notice). The Purchase Agreements include customary representations, indemnities and closing conditions, and contain lock-up and variable-rate transaction restrictions through November 18, 2025 and March 19, 2026, respectively, which the placement agent may waive.

BioCardia is conducting a best-efforts primary offering of 4,800,000 shares of common stock, each sold together with a warrant to buy one additional share, at a combined price of $1.25 per share-and-warrant unit. Gross proceeds are expected to be $6.0 million, with approximately $5.1 million in net proceeds after fees and expenses if all securities are sold. The company expects to use the cash mainly for working capital and to advance its cell therapy programs and delivery partnering business.

After the offering, BioCardia expects 10,608,734 shares of common stock to be outstanding, excluding warrant exercises. The raise would move stockholders’ equity from a deficit to positive $3.2 million, helping address Nasdaq’s minimum equity requirement, and is expected to fund operations at current burn levels into the second quarter of 2026, though additional capital will still be needed.

BioCardia, Inc. filed a Form 8-K to report that on September 18, 2025 it issued a press release announcing the pricing of a public offering involving its common stock and warrants. The filing presents this as a Regulation FD disclosure, meaning the company is sharing this capital markets update broadly with investors. The press release is included as Exhibit 99.1, along with an Inline XBRL cover page data file listed as Exhibit 104.